IL151857A0 - Production of recombinant blood clotting factors in human cell lines - Google Patents
Production of recombinant blood clotting factors in human cell linesInfo
- Publication number
- IL151857A0 IL151857A0 IL15185701A IL15185701A IL151857A0 IL 151857 A0 IL151857 A0 IL 151857A0 IL 15185701 A IL15185701 A IL 15185701A IL 15185701 A IL15185701 A IL 15185701A IL 151857 A0 IL151857 A0 IL 151857A0
- Authority
- IL
- Israel
- Prior art keywords
- human cell
- factor viii
- production
- factor
- clotting factors
- Prior art date
Links
- 239000003114 blood coagulation factor Substances 0.000 title abstract 3
- 210000005260 human cell Anatomy 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 108010054218 Factor VIII Proteins 0.000 abstract 4
- 102000001690 Factor VIII Human genes 0.000 abstract 4
- 229960000301 factor viii Drugs 0.000 abstract 4
- 108091006088 activator proteins Proteins 0.000 abstract 2
- 230000006490 viral transcription Effects 0.000 abstract 2
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00106225A EP1136553A1 (en) | 2000-03-22 | 2000-03-22 | Production of recombinant blood clotting factors in human cell lines |
| US20324900P | 2000-05-08 | 2000-05-08 | |
| PCT/EP2001/003220 WO2001070968A2 (en) | 2000-03-22 | 2001-03-21 | Production of recombinant blood clotting factors in human cell lines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL151857A0 true IL151857A0 (en) | 2003-04-10 |
Family
ID=26070708
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15185701A IL151857A0 (en) | 2000-03-22 | 2001-03-21 | Production of recombinant blood clotting factors in human cell lines |
| IL151857A IL151857A (en) | 2000-03-22 | 2002-09-19 | Generation of recombinant blood clotting factors VIII in cell lines of human origin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL151857A IL151857A (en) | 2000-03-22 | 2002-09-19 | Generation of recombinant blood clotting factors VIII in cell lines of human origin |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7572619B2 (enExample) |
| EP (2) | EP1460131A3 (enExample) |
| JP (1) | JP3894795B2 (enExample) |
| KR (1) | KR100581574B1 (enExample) |
| CN (1) | CN1454257B (enExample) |
| AT (1) | ATE312176T1 (enExample) |
| AU (3) | AU2001254715B2 (enExample) |
| BE (1) | BE2014C077I2 (enExample) |
| BG (1) | BG65930B1 (enExample) |
| BR (1) | BRPI0109494B8 (enExample) |
| CA (1) | CA2404163C (enExample) |
| CZ (1) | CZ303929B6 (enExample) |
| DE (1) | DE60115613T2 (enExample) |
| DK (1) | DK1266006T3 (enExample) |
| EA (1) | EA004317B1 (enExample) |
| EE (1) | EE200200538A (enExample) |
| ES (1) | ES2254403T3 (enExample) |
| FR (1) | FR15C0003I2 (enExample) |
| HR (1) | HRP20020767B1 (enExample) |
| HU (1) | HU228091B1 (enExample) |
| IL (2) | IL151857A0 (enExample) |
| MX (1) | MXPA02009221A (enExample) |
| NO (1) | NO330910B1 (enExample) |
| NZ (1) | NZ521732A (enExample) |
| RS (1) | RS50743B (enExample) |
| SI (1) | SI1266006T1 (enExample) |
| SK (1) | SK287706B6 (enExample) |
| WO (1) | WO2001070968A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0109494B8 (pt) * | 2000-03-22 | 2021-05-25 | Octagene Gmbh | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii |
| MXPA03002256A (es) * | 2000-09-19 | 2003-09-10 | Univ Emory | Factor viii modificado. |
| EP1469064A1 (en) | 2003-04-15 | 2004-10-20 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Expression of proteins in endothelial cells derived from precursor cells from cord blood |
| ATE489105T1 (de) | 2004-03-19 | 2010-12-15 | Baxter Int | Faktor ixa zur behandlung von blutungsstörungen |
| KR100624013B1 (ko) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
| DK2438931T3 (da) | 2004-09-22 | 2013-12-02 | St Jude Childrens Res Hospital | Forbedret ekspression af faktor ix i genterapivektorer |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| CN101120085B (zh) * | 2005-02-11 | 2011-06-08 | 诺和诺德医疗保健公司 | 在包含植物蛋白水解产物的无血清细胞培养液中生产多肽 |
| EP1707634A1 (en) | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
| EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| DK2041270T3 (da) | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
| WO2008134665A1 (en) * | 2007-04-26 | 2008-11-06 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
| EP2198870A4 (en) * | 2007-08-27 | 2011-08-03 | Univ Nagoya Nat Univ Corp | ACTIVATOR FOR BLOOD CREATION FACTOR VII PROMOTER AND ITS USE |
| RU2011110459A (ru) | 2008-08-21 | 2012-09-27 | Октафарма АГ (CH) | Рекомбинантно полученный человеческий фактор viii и ix |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| PT2482841T (pt) | 2009-10-02 | 2019-03-01 | Childrens Hospital Philadelphia | A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães. |
| RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| BRPI1105317A2 (pt) * | 2011-01-24 | 2013-04-30 | Fundacco Hemoct De Ribeirco Preto | produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1 |
| EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| CN102199607B (zh) * | 2011-03-30 | 2012-11-14 | 山西大学 | 重组人凝血因子ix小基因及其ptc突变体稳定细胞株 |
| AU2012257736B2 (en) | 2011-05-13 | 2015-12-10 | Octapharma Ag | A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII |
| TW201307563A (zh) * | 2011-05-19 | 2013-02-16 | Shire Human Genetic Therapies | 純化乙醯肝素－ｎ－硫酸酯酶之方法 |
| EP4011913A1 (en) | 2011-06-30 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| CN102321668A (zh) * | 2011-07-06 | 2012-01-18 | 中国人民解放军军事医学科学院野战输血研究所 | 一种表达重组人凝血因子ⅶ的方法及其专用载体 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| WO2013057219A1 (en) | 2011-10-18 | 2013-04-25 | Csl Behring Gmbh | Method for improving the stability of purified factor viii after reconstitution |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| CN104080909A (zh) | 2011-11-30 | 2014-10-01 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
| MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| GB201210357D0 (en) * | 2012-06-12 | 2012-07-25 | Ucl Business Plc | Factor VIII sequences |
| WO2014008172A2 (en) * | 2012-07-03 | 2014-01-09 | Expression Therapeutics, Llc | High yield suspension cell line, system and method for making same |
| EP3404105A1 (en) | 2012-07-06 | 2018-11-21 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
| CN105452290A (zh) | 2012-11-08 | 2016-03-30 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| CN105025920A (zh) * | 2013-01-24 | 2015-11-04 | 博尔托拉制药公司 | 具有因子Xa衍生物的组织因子途径抑制剂的抑制 |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| EP2853538A1 (en) | 2013-09-27 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Analogues of temporin-SHa and uses thereof |
| SG10201802098UA (en) * | 2014-07-30 | 2018-04-27 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| CN115043945A (zh) | 2014-10-31 | 2022-09-13 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| BR102015012334A2 (pt) | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
| WO2016198499A1 (en) | 2015-06-09 | 2016-12-15 | Glycotope Gmbh | IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES |
| CA2989966C (en) | 2015-08-20 | 2024-04-30 | Albumedix A/S | Albumin variants and conjugates |
| CN105219739A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| KR102450833B1 (ko) | 2016-04-15 | 2022-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 혈우병 a 치료용 유전자 요법 |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| WO2018210771A1 (en) | 2017-05-17 | 2018-11-22 | Octapharma Ag | Method for the production of a recombinant target protein |
| EP3710589A4 (en) | 2017-11-14 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C1S ANTIBODIES AND METHOD OF USING |
| WO2020020364A1 (zh) * | 2018-07-26 | 2020-01-30 | 正大天晴药业集团南京顺欣制药有限公司 | 一种制备重组人凝血因子ⅷ的方法 |
| SG10202106830VA (en) | 2018-08-10 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| AU2019366942B2 (en) | 2018-10-23 | 2025-10-30 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor VIII function |
| CA3137649A1 (en) | 2019-05-15 | 2020-11-19 | Chugai Seiyaku Kabushiki Kaisha | An antigen-binding molecule, a pharmaceutical composition, and a method |
| CA3221235A1 (en) | 2021-06-11 | 2022-12-15 | Ali Ladram | Short antimicrobial peptides |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI86885C (fi) * | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
| JPS6171774A (ja) * | 1984-09-14 | 1986-04-12 | Sony Corp | テレビジヨンカメラ装置のビ−ム電流制御装置 |
| AU5864086A (en) * | 1985-04-22 | 1986-11-18 | Genetics Institute Inc. | High yield production of active factor ix |
| DE3785102T2 (de) * | 1986-01-03 | 1993-07-22 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ-proteinen. |
| US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
| FR2638643B1 (fr) * | 1988-11-09 | 1991-04-12 | Transgene Sa | Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants |
| CA2135744A1 (en) * | 1989-11-17 | 1991-05-18 | Barbara Chapman | Protein complexes having factor viii:c activity and production thereof |
| SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| FI923347A0 (fi) * | 1990-01-26 | 1992-07-23 | Immuno Ag | Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus. |
| US5445953A (en) * | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
| CA2162497A1 (en) * | 1993-06-10 | 1994-12-22 | Sheila Connelly | Adenoviral vectors for treatment of hemophilia |
| EP0951544A2 (en) * | 1996-07-03 | 1999-10-27 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of human disease |
| US6114148C1 (en) * | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| JP2002517180A (ja) * | 1997-12-05 | 2002-06-18 | ジ・イミユーン・リスポンス・コーポレーシヨン | 増大された発現を示す新規ベクターおよび遺伝子 |
| US6358703B1 (en) * | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| JP2002537311A (ja) | 1999-02-19 | 2002-11-05 | オクタジーン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ホルモン−ホルモン受容体の複合体および核酸構築物、並びに遺伝子治療におけるそれらの使用 |
| WO2001012836A1 (en) * | 1999-08-13 | 2001-02-22 | Fred Hutchinson Cancer Research Center | Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof |
| BRPI0109494B8 (pt) * | 2000-03-22 | 2021-05-25 | Octagene Gmbh | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii |
| WO2003009237A1 (en) * | 2001-07-18 | 2003-01-30 | Skaginn Hf. | A method and apparatus for relating information of a processed object to an operator |
-
2001
- 2001-03-21 BR BRPI0109494A patent/BRPI0109494B8/pt not_active IP Right Cessation
- 2001-03-21 MX MXPA02009221A patent/MXPA02009221A/es active IP Right Grant
- 2001-03-21 NZ NZ521732A patent/NZ521732A/en not_active IP Right Cessation
- 2001-03-21 AU AU2001254715A patent/AU2001254715B2/en not_active Expired
- 2001-03-21 RS YUP-710/02A patent/RS50743B/sr unknown
- 2001-03-21 JP JP2001569351A patent/JP3894795B2/ja not_active Expired - Lifetime
- 2001-03-21 SK SK1504-2002A patent/SK287706B6/sk not_active IP Right Cessation
- 2001-03-21 HR HR20020767A patent/HRP20020767B1/xx not_active IP Right Cessation
- 2001-03-21 CN CN018097456A patent/CN1454257B/zh not_active Expired - Lifetime
- 2001-03-21 DE DE60115613T patent/DE60115613T2/de not_active Expired - Lifetime
- 2001-03-21 CZ CZ20023166A patent/CZ303929B6/cs not_active IP Right Cessation
- 2001-03-21 AT AT01927769T patent/ATE312176T1/de active
- 2001-03-21 WO PCT/EP2001/003220 patent/WO2001070968A2/en not_active Ceased
- 2001-03-21 EE EEP200200538A patent/EE200200538A/xx unknown
- 2001-03-21 EP EP04009279A patent/EP1460131A3/en not_active Withdrawn
- 2001-03-21 AU AU5471501A patent/AU5471501A/xx active Pending
- 2001-03-21 SI SI200130501T patent/SI1266006T1/sl unknown
- 2001-03-21 EP EP01927769A patent/EP1266006B1/en not_active Expired - Lifetime
- 2001-03-21 KR KR1020027012443A patent/KR100581574B1/ko not_active Expired - Lifetime
- 2001-03-21 EA EA200201008A patent/EA004317B1/ru active Protection Beyond IP Right Term
- 2001-03-21 US US10/239,498 patent/US7572619B2/en not_active Expired - Lifetime
- 2001-03-21 IL IL15185701A patent/IL151857A0/xx unknown
- 2001-03-21 ES ES01927769T patent/ES2254403T3/es not_active Expired - Lifetime
- 2001-03-21 DK DK01927769T patent/DK1266006T3/da active
- 2001-03-21 CA CA002404163A patent/CA2404163C/en not_active Expired - Lifetime
- 2001-03-21 HU HU0300588A patent/HU228091B1/hu unknown
-
2002
- 2002-09-19 IL IL151857A patent/IL151857A/en active IP Right Grant
- 2002-09-19 NO NO20024475A patent/NO330910B1/no not_active IP Right Cessation
- 2002-09-26 BG BG107152A patent/BG65930B1/bg unknown
-
2006
- 2006-05-02 AU AU2006201848A patent/AU2006201848A1/en not_active Abandoned
-
2014
- 2014-12-29 BE BE2014C077C patent/BE2014C077I2/fr unknown
-
2015
- 2015-01-20 FR FR15C0003C patent/FR15C0003I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU5471501A (en) | Production of recombinant blood clotting factors in human cell lines | |
| EP1395293A4 (en) | LENTIVIRAL VECTORS ENCODING COAGULATION FACTORS USEFUL FOR GENE THERAPY | |
| IL160897A0 (en) | Human coagulation factor vii polypeptides | |
| CA2400295A1 (en) | Modified factor viii | |
| DE69841982D1 (de) | Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie | |
| AU2001254624A1 (en) | Human coagulation factor vii variants | |
| DE69942280D1 (de) | Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren | |
| JPS6485096A (en) | Hybrid human protein c and biotechnological synthesis thereof | |
| ES8800347A1 (es) | Metodo para preparar uroquinasa de una sola cadena resistente a proteasas | |
| GB0218252D0 (en) | Fusion protein having enhanced in vivo activity of erythropoietin | |
| MXPA04003944A (es) | Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto. | |
| ES8607730A1 (es) | Procedimiento para producir el factor viii-c humano | |
| AP2000001999A0 (en) | Gene therapy method. | |
| DE69227921D1 (de) | Herstellung von Proteinen mittels Protein 7B2 | |
| ATE513033T1 (de) | Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen | |
| WO2002050111A3 (en) | Isolated laminin 10 | |
| KR890006815A (ko) | 산성 섬유아세포 생장인자의 돌연변이체 | |
| DE602004028239D1 (de) | Protease, für die protease codierende dna und verfahren zur herstellung der protease | |
| EP1679372A4 (en) | NEW PLEXIN POLYPEPTIDE, THIS CODING DNA AND USE THEREOF | |
| UA81601C2 (ru) | Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки |